The Biden administration this week pleaded with states to slow the post-pandemic removal of beneficiaries from their Medicaid rolls, as government data shows more than a million Americans have lost coverage since pandemic protections ended in April.
Novartis offers glimpse at BTK inhibitor plans beyond lead indications: #AAD24
Novartis provided a peek Saturday of how it might expand development of its experimental drug remibrutinib, a BTK inhibitor being tested in a range of
March 10, 2024